Abstracts tagged "Compliance"

Abstract Number: 2039 • 2016 ACR/ARHP Annual Meeting
Assessing Barriers to Uveitis Screening in Patients with JIA: A Qualitative Study
Laura Ballenger¹, Kyla Driest² and Stacy P. Ardoin³, ¹Nationwide Children's Hospital, Columbus, OH, ²Rheumatology, Nationwide Children's Hospital, Columbus, OH, ³Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: Uveitis is a major complication in patients with juvenile idiopathic arthritis (JIA) can be completely asymptomatic until vision loss develops. In order to prevent ocular…
Abstract Number: 2254 • 2016 ACR/ARHP Annual Meeting
Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Laurent Chanroux, Fara Mboge and Denise Baldock, Therapy Watch, Research Partnership, London, United Kingdom
Background/Purpose: Biologic agents (bDMARDs) have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim of our research…
Abstract Number: 2532 • 2016 ACR/ARHP Annual Meeting
Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis
Bo Katic¹, Ana Maria Rodriguez¹, Chris Curran¹, Michel Brethous², Corrado Bernasconi², Jan Michael Nebesky² and William Reiss³, ¹Patients Like Me (PLM), Cambridge, MA, ²F. Hoffmann-La Roche, Basel, Switzerland, ³Genentech, South San Francisco, CA
Background/Purpose: US-based adult patients self-reporting RA were recruited from an online health-sharing network, PatientsLikeMe. Patients were invited to fill out a cross-sectional Web-based survey if…
Abstract Number: 322 • 2016 ACR/ARHP Annual Meeting
The Activating Patients at Risk for Osteoporosis Study: A Randomized Trial within the Global Longitudinal Study of Osteoporosis in Women Cohort
Maria I. Danila¹, Ryan C. Outman¹, Elizabeth J. Rahn², Amy S. Mudano³, David T. Redden⁴, Peng Li⁴, Fred A. Anderson⁵, Julia P. Anderson⁶, Susan L. Greenspan⁷, Andrea Z. LaCroix^6,8, Jeri W. Nieves⁹, Stuart L. Silverman¹⁰, Ethel S. Siris¹¹, Nelson B. Watts¹², Michael J. Miller¹³, Jeffrey R. Curtis¹⁴, Amy H. Warriner³, Nicole C. Wright¹⁵ and Kenneth G. Saag¹⁶, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, Division of Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Group Health Cooperative, Seattle, WA, ⁷University of Pittsburgh, Pittsburgh, PA, ⁸University of California San Diego, La Jolla, CA, ⁹Helen Hayes, West Haverstraw, NY, ¹⁰Cedars-Sinai Medical Center, Los Angeles, CA, ¹¹Columbia University Medical Center, New York, NY, ¹²Endocrinology, Diabetes & Metabolism, University of Cincinnati, Cincinnati, OH, ¹³University of Oklahoma, Tulsa, OK, ¹⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁶Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: To improve the rate of osteoporosis medication use in women with a prior fracture we developed and implemented a tailored, educational, direct-to-patient video intervention…
Abstract Number: 2829 • 2016 ACR/ARHP Annual Meeting
Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis
Eleana Ntatsaki¹, Alba Velo Garcia², Alan D. Salama³ and David A. Isenberg⁴, ¹Centre for Rheumatology, University College London, London, United Kingdom, ²Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, ³Centre for Nephrology, University College London, London, United Kingdom, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential…
Abstract Number: 424 • 2016 ACR/ARHP Annual Meeting
Adherence to American College of Rheumatology Immunization Recommendations for Rheumatoid Arthritis Patients in a Tertiary Care Health System and Opportunities to Close the Gap
Maryann Kimoto¹, Mary Chester M. Wasko² and Tarun S. Sharma³, ¹Internal Medicine, Internal Medicine Residency Program, Allegheny Health Network, Pittsburgh, PA, ²Lupus Center, Pittsburgh, PA, ³Rheumatology, Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, PA
Background/Purpose: A total of 85 adult RA patients were identified. The mean age was 61.5 yrs, 84.7% were female, 85.9% were Caucasian, and the mean…
Abstract Number: 3088 • 2016 ACR/ARHP Annual Meeting
Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Vandana Ahluwalia¹, Mohammad Movahedi^2,3, Emmanouil Rampakakis², Angela Cesta³, Xiuying Li³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹Brampton Civic Hospital, Brampton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite the availability of safe and effective treatments and the establishment of treatment guidelines, real-world effectiveness remains suboptimal largely due to low patient adherence…
Abstract Number: 432 • 2016 ACR/ARHP Annual Meeting
Monitoring Hepatitis B Screening Compliance in Patients with Rheumatoid Arthritis (RA) Receiving Anti-TNF Therapy
Vedashree Panthulu¹ and John Waterman², ¹Rheumatology, University of Connecticut Health Center, Farmington, CT, ²Rheumatology, Connecticut VA Healthcare System, Newington, CT
Background/Purpose: The risk of infection in patients with RA is higher than in comparable patients but still the vaccination rates in RA patients are low. …
Abstract Number: 3153 • 2016 ACR/ARHP Annual Meeting
Automated Cell Phone Monitoring of Disease Activity and Medication Adherence in Early Rheumatoid Arthritis
Laura Kuusalo^1,2, Hannu Kautiainen³, Tuulikki Sokka-Isler⁴, Toini Uutela⁵, Laura Pirilä², Timo Yli-Kerttula⁶, Markku J Kauppi^7,8, Tuomas Rannio⁹, Kirsi Paalanen¹⁰, Arto Kokko⁹, Juha Asikainen⁹, Jelena Borodina¹⁰, Johanna Paltta², Kari Laiho¹¹, Andrus Mullanmaa¹², Kari Puolakka¹² and SandRA Study Group, ¹University of Turku, Turku, Finland, ²Turku University Hospital, Turku, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁵Lapland Central Hospital, Rovaniemi, Finland, ⁶Sairaalantie 3, Satakunta Central Hospital, Rauma, Finland, ⁷School of Medicine, University of Tampere, Tampere, Finland, ⁸Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland, ⁹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹⁰Jyvaskyla Central Hospital, Jyvaskyla, Finland, ¹¹Päijät-Häme Central Hospital, Lahti, Finland, ¹²South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: Remission targeted treatment of early RA requires frequent monitoring. However, in clinical practice monitoring frequency is not always optimal due to factors like limited…
Abstract Number: 525 • 2016 ACR/ARHP Annual Meeting
Predictors of Health Care Drop-out in an Inception Cohort of Patients with Early Onset Rheumatoid Arthritis
Irazú Contreras-Yáñez¹ and Virginia Pascual-Ramos², ¹Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico
Background/Purpose: The impact of inadequate therapy behavior in rheumatoid arthritis (RA) patient outcomes may be amplified by the fact that almost all individuals with poor…
Abstract Number: 3195 • 2016 ACR/ARHP Annual Meeting
Patterns and Predictors of Hydroxychloroquine Nonadherence in a Nationwide Cohort of Medicaid Beneficiaries with Systemic Lupus Erythematosus
Candace H. Feldman¹, Jamie E. Collins², Zhi Zhang³, Daniel H. Solomon⁴, Karen H. Costenbader¹ and Ichiro Kawachi⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ⁵Social and Behavioral Sciences, Harvard T. H. Chan School of Public Health, Boston, MA
Background/Purpose: Hydroxychloroquine (HCQ) is the standard of care medication for most SLE patients, however cross-sectional studies suggest that nonadherence is common. Similar to the fluctuating…
Abstract Number: 531 • 2016 ACR/ARHP Annual Meeting
Disease Activity and Physical Fatigue As Related to Adherence and Health Literacy in Patients with Rheumatoid Arthritis
Jens Gert Kuipers¹, Michael Koller², Florian Zeman², Karolina Mueller³ and Ulrich Rueffer⁴, ¹Department of Rheumatology, Red Cross Hospital Bremen, Bremen, Germany, ²Center of Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ³Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, ⁴German Fatigue Society, Cologne, Germany
Disease activity and physical fatigue as related to adherence and health literacy in patients with rheumatoid arthritis J. G. Kuipers1, M. Koller2, F. Zeman2, K.…
Abstract Number: 614 • 2016 ACR/ARHP Annual Meeting
Canadian Study of Outcomes in Adalimumab (HUMIRA®) Patients with Support for Adherence – Results from the Companion Study
Sebastien Gerega¹, Brad Millson¹, Louis Bessette², John Marshall³, Gerald Lebovic^4,5, Michael Sung¹, Driss Oraichi¹, Sandra Gazel⁶, Tania Gaetano⁶, Martin Latour⁶ and Marie-Claude Laliberté⁶, ¹IMS Brogan, Kirkland, QC, Canada, ²Centre Hospitalier de l'Université Laval, Quebec, QC, Canada, ³Department of Medicine, Division of Gastroenterology, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, ON, Canada, ⁴Applied Health Research Centre, St. Michael’s Hospital, Toronto, ON, Canada, ⁵Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ⁶AbbVie, Inc., St.Laurent, QC, Canada
Background/Purpose: Adalimumab (ADA) is a TNF-alpha inhibitor indicated for use in various inflammatory autoimmune diseases including rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis…
Abstract Number: 1496 • 2015 ACR/ARHP Annual Meeting
Uncovering and Addressing Issues Related to Medication Adherence Among Patients with Rheumatic Diseases: A Patient Navigator Pilot Program
Anarosa Campos¹, Alyssa Wohlfahrt¹, Yuanyu Lo¹, Maura D. Iversen², Elena Massarotti³, Daniel H. Solomon⁴ and Candace H. Feldman⁵, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Northeastern University, Department of Physical Therapy, and Brigham & Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy, Brigham and Women's Hospital,Harvard Medical School, Boston, MA
Background/Purpose: Poor adherence to medications is a common problem among rheumatology patients that can lead to irreversible negative outcomes. We piloted an intervention using patient…
Abstract Number: 1556 • 2015 ACR/ARHP Annual Meeting
The Medication Information-Seeking Behaviors of Rheumatoid Arthritis Patients Who Are Prescribed a New DMARD
Delesha Carpenter¹, Lorie Geryk², Courtney Arrindell³, Beth Jonas⁴ and Susan J. Blalock⁵, ¹Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Asheville, NC, ²Division of Pharmaceutical Outcomes and Policy, University of North Carolina Eshelman School of Pharmacy, Chapel Hill, NC, ³University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁴Thurston Arthritis Research Ct, UNC-Chapel Hill, Chapel Hill, NC, ⁵School of Pharmacy, UNC at Chapel Hill, Chapel Hill, NC
Background/Purpose: We present preliminary longitudinal data about the information-seeking behaviors and medication experiences of RA patients who are prescribed a new DMARD. Methods: We recruited…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].